

# Magdalena Harris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1781867/publications.pdf>

Version: 2024-02-01

76  
papers

2,050  
citations

236925

25  
h-index

265206

42  
g-index

79  
all docs

79  
docs citations

79  
times ranked

2020  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and factors associated with chronic venous insufficiency, leg ulceration and deep vein thrombosis among people who inject drugs in London, UK. <i>Drug and Alcohol Review</i> , 2022, 41, 677-685.	2.1	5
2	Overdose prevention centres in the UK. <i>Lancet Public Health</i> , The, 2022, 7, e196-e197.	10.0	10
3	Barriers to management of opioid withdrawal in hospitals in England: a document analysis of hospital policies on the management of substance dependence. <i>BMC Medicine</i> , 2022, 20, 151.	5.5	7
4	The United Kingdom's first unsanctioned overdose prevention site; A proof-of-concept evaluation. <i>International Journal of Drug Policy</i> , 2022, 104, 103670.	3.3	14
5	Injecting drug use, the skin and vasculature. <i>Addiction</i> , 2021, 116, 1914-1924.	3.3	19
6	Ecologies of drug war and more-than-human health: The case of a chemical at war with a plant. <i>International Journal of Drug Policy</i> , 2021, 89, 103067.	3.3	9
7	Conceptualising hepatitis C stigma: A thematic synthesis of qualitative research. <i>International Journal of Drug Policy</i> , 2021, 96, 103320.	3.3	23
8	Social and structural determinants of injecting-related bacterial and fungal infections among people who inject drugs: protocol for a mixed studies systematic review. <i>BMJ Open</i> , 2021, 11, e049924.	1.9	12
9	Creativity, care and "messy" drug use: A collective history of the early days of peer-led needle exchange in Dunedin, New Zealand. <i>International Journal of Drug Policy</i> , 2021, 98, 103386.	3.3	5
10	"Nothing about us, without us" Negotiating the personal and professional as activists and academics who use drugs. <i>International Journal of Drug Policy</i> , 2021, 98, 103533.	3.3	3
11	Frequency of health care utilization by adults who use illicit drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2020, 115, 1011-1023.	3.3	88
12	Normalised pain and severe health care delay among people who inject drugs in London: Adapting cultural safety principles to promote care. <i>Social Science and Medicine</i> , 2020, 260, 113183.	3.8	48
13	Prevalence and severity of abscesses and cellulitis, and their associations with other health outcomes, in a community-based study of people who inject drugs in London, UK. <i>PLoS ONE</i> , 2020, 15, e0235350.	2.5	27
14	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. <i>PLoS ONE</i> , 2020, 15, e0235715.	2.5	12
15	From stagnation to elimination: tracking hepatitis C elimination policy implementation in Europe in partnership with patient organizations. <i>Journal of Hepatology</i> , 2020, 73, S793-S794.	3.7	0
16	High prevalence of albuminuria amongst people who inject drugs: A cross-sectional study. <i>Scientific Reports</i> , 2020, 10, 7059.	3.3	7
17	Incidence and treatment costs of severe bacterial infections among people who inject heroin: A cohort study in South London, England. <i>Drug and Alcohol Dependence</i> , 2020, 212, 108057.	3.2	19
18	More-than-harm reduction: Engaging with alternative ontologies of "movement" in UK drug services. <i>International Journal of Drug Policy</i> , 2020, 82, 102771.	3.3	20

#	ARTICLE	IF	CITATIONS
19	Factors associated with skin and soft tissue infections among people who inject drugs in the United Kingdom: A comparative examination of data from two surveys. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108080.	3.2	19
20	An urgent impetus for action: safe inhalation interventions to reduce COVID-19 transmission and fatality risk among people who smoke crack cocaine in the United Kingdom. <i>International Journal of Drug Policy</i> , 2020, 83, 102829.	3.3	27
21	Commentary on Hancocket al. (2020): Low dead space syringes are just one component of an integrated package of care needed to tackle HCV and social exclusion among people who inject drugs. <i>Addiction</i> , 2020, 115, 714-715.	3.3	1
22	Navigating environmental constraints to injection preparation: the use of saliva and other alternatives to sterile water among unstably housed PWID in London. <i>Harm Reduction Journal</i> , 2020, 17, 24.	3.2	26
23	Title is missing!. , 2020, 15, e0235715.		0
24	Title is missing!. , 2020, 15, e0235715.		0
25	Title is missing!. , 2020, 15, e0235715.		0
26	Title is missing!. , 2020, 15, e0235715.		0
27	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) â€” a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	1.9	30
28	The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virusâ€infectected people who inject drugs in England. <i>Addiction</i> , 2019, 114, 1113-1122.	3.3	33
29	Injecting-related health harms and overuse of acidifiers among people who inject heroin and crack cocaine in London: a mixed-methods study. <i>Harm Reduction Journal</i> , 2019, 16, 60.	3.2	28
30	Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination. <i>Critical Public Health</i> , 2019, 29, 260-273.	2.4	14
31	Hepâ€CORE: a crossâ€sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017. <i>Journal of the International AIDS Society</i> , 2018, 21, e25052.	3.0	17
32	Understanding hepatitis C intervention successâ€”Qualitative findings from the Hep<scp>CATT</scp> study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 762-770.	2.0	23
33	Drawing attention to a neglected injectingâ€related harm: a systematic review of AA amyloidosis among people who inject drugs. <i>Addiction</i> , 2018, 113, 1790-1801.	3.3	13
34	â€œItâ€™s Not Much of a Lifeâ€ The Benefits and Ethics of Using Life History Methods With People Who Inject Drugs in Qualitative Harm Reduction Research. <i>Qualitative Health Research</i> , 2018, 28, 1123-1134.	2.1	12
35	Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: Do we know enough to promote it?. <i>International Journal of Drug Policy</i> , 2018, 58, 31-36.	3.3	58
36	A qualitative assessment of the acceptability of hepatitis C remote self-testing and self-sampling amongst people who use drugs in London, UK. <i>BMC Infectious Diseases</i> , 2018, 18, 281.	2.9	22

#	ARTICLE	IF	CITATIONS
37	Patient monitoring of changes in the European policy response to viral hepatitis C treatment: Hep-CORE findings from 2016 to 2017. <i>Journal of Hepatology</i> , 2018, 68, S144-S145.	3.7	0
38	â€œCare and Preventâ€™: rationale for investigating skin and soft tissue infections and AA amyloidosis among people who inject drugs in London. <i>Harm Reduction Journal</i> , 2018, 15, 23.	3.2	20
39	Caring and curing: Considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes. <i>International Journal of Drug Policy</i> , 2018, 60, 24-32.	3.3	28
40	Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment â€benefitâ€™. <i>International Journal of Drug Policy</i> , 2017, 47, 161-168.	3.3	41
41	Tensions in relation: How peer support is experienced and received in a hepatitis C treatment intervention. <i>International Journal of Drug Policy</i> , 2017, 47, 221-229.	3.3	27
42	Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. <i>International Journal of Drug Policy</i> , 2017, 47, 26-33.	3.3	53
43	Risk Environments and the Ethics of Reducing Drug-Related Harms. <i>American Journal of Bioethics</i> , 2017, 17, 46-48.	0.9	8
44	Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. <i>International Journal of Drug Policy</i> , 2017, 47, 47-50.	3.3	21
45	Opiate Injectionâ€™Associated Skin, Soft Tissue, and Vascular Infections, England, UK, 1997â€™2016. <i>Emerging Infectious Diseases</i> , 2017, 23, 1400-1403.	4.3	48
46	Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom. <i>Journal of Viral Hepatitis</i> , 2016, 23, 479-486.	2.0	35
47	The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs. <i>Hepatology, Medicine and Policy</i> , 2016, 1, 14.	1.7	5
48	â€œThree in the Roomâ€™: <i>Qualitative Health Research</i> , 2015, 25, 1689-1699.	2.1	42
49	Fire in the vein: Heroin acidity and its proximal effect on usersâ€™ health. <i>International Journal of Drug Policy</i> , 2015, 26, 1103-1110.	3.3	57
50	Human rights and access to hepatitis C treatment for people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1072-1080.	3.3	52
51	The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?. <i>International Journal of Drug Policy</i> , 2015, 26, 963-969.	3.3	27
52	â€œt's Russian rouletteâ€™: Adulteration, adverse effects and drug use transitions during the 2010/2011 United Kingdom heroin shortage. <i>International Journal of Drug Policy</i> , 2015, 26, 51-58.	3.3	31
53	Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis. <i>BMC Infectious Diseases</i> , 2014, 14, S18.	2.9	5
54	Hepatitis C testing for people who inject drugs in the United Kingdom: Why is uptake so low?. <i>Drugs: Education, Prevention and Policy</i> , 2014, 21, 333-342.	1.3	10

#	ARTICLE	IF	CITATIONS
55	â€œI canâ€™t do this, itâ€™s too muchâ€ building social inclusion in cancer diagnosis and treatment experiences of Aboriginal people, their carers and health workers. <i>International Journal of Public Health</i> , 2014, 59, 373-379.	2.3	37
56	Injecting practices in sexual partnerships: Hepatitis C transmission potentials in a â€risk equivalenceâ€™ framework. <i>Drug and Alcohol Dependence</i> , 2013, 132, 617-623.	3.2	30
57	Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. <i>Harm Reduction Journal</i> , 2013, 10, 7.	3.2	206
58	Methadone diversion as a protective strategy: The harm reduction potential of â€generous constraintsâ€™. <i>International Journal of Drug Policy</i> , 2013, 24, e43-e50.	3.3	81
59	The â€do-it-yourselfâ€™ New Zealand injecting scene: Implications for harm reduction. <i>International Journal of Drug Policy</i> , 2013, 24, 281-283.	3.3	20
60	Breaking worse: The emergence of krokodil and excessive injuries among people who inject drugs in Eurasia. <i>International Journal of Drug Policy</i> , 2013, 24, 265-274.	3.3	75
61	Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting. <i>Social Science and Medicine</i> , 2013, 83, 19-26.	3.8	65
62	Negotiating access to medical treatment and the making of patient citizenship: the case of hepatitis C treatment. <i>Sociology of Health and Illness</i> , 2013, 35, 1023-1044.	2.1	49
63	Health literacy in relation to cancer: addressing the silence about and absence of cancer discussion among Aboriginal people, communities and health services. <i>Health and Social Care in the Community</i> , 2013, 21, n/a-n/a.	1.6	31
64	One size fits all? The discursive framing of cultural difference in health professional accounts of providing cancer care to Aboriginal people. <i>Ethnicity and Health</i> , 2013, 18, 433-447.	2.5	21
65	Hepatitis C Avoidance in Injection Drug Users: A Typology of Possible Protective Practices. <i>PLoS ONE</i> , 2013, 8, e77038.	2.5	11
66	Staying Safe From Hepatitis C. <i>Qualitative Health Research</i> , 2012, 22, 31-42.	2.1	24
67	Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs. <i>Addiction</i> , 2012, 107, 1090-1096.	3.3	68
68	Pleasure and Guilt: Alcohol Use and Hepatitis C. <i>Qualitative Health Research</i> , 2010, 20, 1262-1271.	2.1	6
69	A diagnosis of hepatitis C - insights from a study on patients' experiences. <i>Australian Family Physician</i> , 2010, 39, 589-92.	0.5	20
70	Relapse to Injecting Drug Use: A Hepatitis C Treatment Concern. <i>Contemporary Drug Problems</i> , 2009, 36, 303-326.	1.6	3
71	Injecting, Infection, Illness: Abjection and Hepatitis C Stigma. <i>Body and Society</i> , 2009, 15, 33-51.	0.7	70
72	Troubling biographical disruption: narratives of unconcern about hepatitis C diagnosis. <i>Sociology of Health and Illness</i> , 2009, 31, 1028-1042.	2.1	43

#	ARTICLE	IF	CITATIONS
73	Enhanced primary care items. Their use in diabetes management. Australian Family Physician, 2001, 30, 1134-40.	0.5	7
74	Skin infections in Tanna, Vanuatu in 1989. Papua and New Guinea Medical Journal, 1992, 35, 137-43.	1.0	7
75	Childhood immunisation advisory service for general practitioners. Australian Family Physician, 1991, 20, 1495, 1497, 1501-2.	0.5	0
76	Alcohol Related Hospital Admissions in a Country Town. Australian Drug and Alcohol Review, 1987, 6, 195-198.	0.1	14